Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of Divided Dose Oral Sinemet in Healthy Subjects
NCT02486432Phase 1Completed
- Sponsor
- NeuroDerm Ltd.
- Start
- Apr 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of levodopa and carbidopa in Parkinson's disease (PD), sponsored by NeuroDerm Ltd. Primary endpoint: Safety and tolerability of oral doses of levodopa and carbidopa at 5 weeks. Started Apr 2015; status: completed.
02
Drugs
levodopacarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02486432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02486432.